Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0210996
Title: Trinucleotide repeat expansion length as a predictor of the clinical progression of Fuchs' Endothelial Corneal Dystrophy
Authors: Soh Y.Q.
Lim G.P.S.:rp09077 
Htoon H.M. 
Gong X.
Vinod Mootha V.
Vithana E.N. 
Kocaba V.
Mehta J.S. 
Keywords: adult
allele
Article
cell density
central corneal thickness
cohort analysis
congenital cornea dystrophy
disease course
disease severity
endothelium cell
ethnicity
female
follow up
human
keratoplasty
leukocyte count
major clinical study
male
prognosis
risk assessment
trinucleotide repeat
Issue Date: 2019
Publisher: Public Library of Science
Citation: Soh Y.Q., Lim G.P.S.:rp09077, Htoon H.M., Gong X., Vinod Mootha V., Vithana E.N., Kocaba V., Mehta J.S. (2019). Trinucleotide repeat expansion length as a predictor of the clinical progression of Fuchs' Endothelial Corneal Dystrophy. PLoS ONE 14 (1) : e0210996. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0210996
Abstract: Purpose To determine if CTG18.1 TNR expansion length prognosticates the clinical progression of Fuchs' Endothelial Corneal Dystrophy (FECD). Methods This was a prospective cohort study. A total of 51 patients with newly diagnosed FECD were recruited and followed-up over a period of 12 years, from November 2004 to April 2016. Baseline clinical measurements included central corneal thickness (CCT), endothelial cell density (ECD) and CTG18.1 TNR expansion length from peripheral leukocytes, with yearly repeat measurements of CCT and ECD. A patient was defined to have experienced significant clinical progression and to have developed Threshold Disease if any of these criteria were fulfilled in either eye: a) CCT increased to >700?m, b) ECD decreased to <700 cells/ mm 2 , or c) underwent keratoplasty for treatment of FECD. Results Patients were categorized as having at least one allele whose maximum allele length was equal to or greater than 40 repeats (L40, n = 22, 43.1%), or having both alleles shorter than 40 repeats (L<40). Threshold Disease rates at the 5-year time point were 87.5% for the L40 group and 47.8% for the L<40 group (p = 0.012). This difference narrowed and was no longer statistically significant at the 8-years (92.9% vs 78.9%, p = 0.278) and 10-years (92.9% vs 84.2%, p = 0.426) time points. Conclusions L40 patients are at greater risk of FECD progression and development of Threshold Disease within the first 5 years following diagnosis. © 2019 Soh et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/165887
ISSN: 19326203
DOI: 10.1371/journal.pone.0210996
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0210996.pdf1.67 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.